HOWL Werewolf Therapeutics, Inc.
USHealthcareAs of 2026-07-08 16:00
Why HOWL matters now
Werewolf Therapeutics, Inc. (HOWL) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.36 with +4.59% on the session and $17.5M in market capitalization; recent performance reads 1-month -18.00% and YTD -44.55%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-13.5M, and EPS of $-0.28. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -304.2%.
The latest indexable market news headline is "Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.50; recent insider activity includes RA CAPITAL MANAGEMENT, L.P. filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.40
P/S
0.00
EV/EBITDA
-0.17
DCF Value
$1.02
FCF Yield
-304.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-208.2%
ROA
-97.0%
ROIC
-103.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-13.5M | $-0.28 |
| Q4 2025 | $0.00 | $-8.4M | $-0.17 |
| FY 2025 | $0.00 | $-60.8M | $-1.33 |
| Q3 2025 | $0.00 | $-16.4M | $-0.36 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.50
Target (Median)
$6.50
Target Range
$1.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.29
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.